GW Pharmaceuticals

GW Pharmaceuticals Plc is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics across a broad range of disease areas through its proprietary cannabinoid product platform. The company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the United States by its U.S. subsidiary, Greenwich Biosciences, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. The company has additional cannabinoid product candidates, notably nabiximols, and is advancing multiple late-stage clinical programs to seek FDA approval for the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The company also has other cannabinoid-based products in clinical trials for autism and schizophrenia.